PUMA BIOTECHNOLOGY, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
10880 WILSHIRE BLVD., LOS ANGELES, CA, 90024
Mailing Address
10880 WILSHIRE BLVD., LOS ANGELES, CA, 90024
Phone
(424) 248-6500
Fiscal Year End
1231
EIN
770683487
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | November 13, 2025 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Nerlynx net product revenue grew to $220.5 million in 2025, up from $200.1 million in 2024.
- Net loss improved significantly to $45.3 million in 2025, down from $55.8 million in 2024, reflecting improved operational efficiency.
Insider Trading
SELL
3 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.